VEGFA and neoplasm: We found that rotarod performance decreased as tumor size increased in the control group (Figure 3A); in the anti-VEGF-treated group, where the treatments reduced tumor size, rotarod performance significantly increased (Figure 3B); in the crizotinib-treated group, where the treatment stabilized tumor growth, rotarod performance improved (Figure 3C); and in the losartan treatment groups, where treatment did not affect tumor growth, rotarod performance decreased as the tumors grew (Figure 3D).